Silence Signs Takeda Deal And Sets Sights On US
Business As Usual After Abrupt CEO Exit
Executive Summary
The resignation of David Horn Solomon last month was a setback for Silence but the company believes it will benefit from the growing prominence given to RNAi technology.
You may also be interested in...
Silence Therapeutics Continues Transformation, Improves US Visibility
The UK's Silence Therapeutics is moving its candidate products into early clinical studies in cardiovascular diseases and improving its visibility with a NASDAQ listing.
OliX Moves Into Spotlight Amid Strong RNAi Interest, New Platform
With recently secured platform technology and various programs now entering clinical trials, South Korean RNAi therapeutics company OliX Pharmaceuticals is hoping to reach multiple licensing deals by next year.
Stockwatch: Is Alnylam’s Rare Disease Business Model Sustainable?
Alnylam’s fourth-quarter and full-year 2019 earnings announcement was only one of eight announcements made by the company since early February. With the fundamental basis of its orphan drug business model still unvalidated by a profit, perhaps the more recent announcements are meant to distract investors’ attention with different metrics.